These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

798 related articles for article (PubMed ID: 33523846)

  • 41. Design, synthesis and biological evaluation of novel L-ascorbic acid-conjugated pentacyclic triterpene derivatives as potential influenza virus entry inhibitors.
    Wang H; Xu R; Shi Y; Si L; Jiao P; Fan Z; Han X; Wu X; Zhou X; Yu F; Zhang Y; Zhang L; Zhang L; Zhou D; Xiao S
    Eur J Med Chem; 2016 Mar; 110():376-88. PubMed ID: 26866456
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Identification of the Receptor-Binding Domain of the Spike Glycoprotein of Human Betacoronavirus HKU1.
    Qian Z; Ou X; Góes LG; Osborne C; Castano A; Holmes KV; Dominguez SR
    J Virol; 2015 Sep; 89(17):8816-27. PubMed ID: 26085157
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Topology-Matching Design of an Influenza-Neutralizing Spiky Nanoparticle-Based Inhibitor with a Dual Mode of Action.
    Nie C; Parshad B; Bhatia S; Cheng C; Stadtmüller M; Oehrl A; Kerkhoff Y; Wolff T; Haag R
    Angew Chem Weinheim Bergstr Ger; 2020 Sep; 132(36):15662-15666. PubMed ID: 32836497
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Broad-spectrum antivirals of protoporphyrins inhibit the entry of highly pathogenic emerging viruses.
    Lu S; Pan X; Chen D; Xie X; Wu Y; Shang W; Jiang X; Sun Y; Fan S; He J
    Bioorg Chem; 2021 Feb; 107():104619. PubMed ID: 33450541
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A "building block" approach to the new influenza A virus entry inhibitors with reduced cellular toxicities.
    Lin D; Li F; Wu Q; Xie X; Wu W; Wu J; Chen Q; Liu S; He J
    Sci Rep; 2016 Mar; 6():22790. PubMed ID: 26952867
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antibody-dependent enhancement of influenza disease promoted by increase in hemagglutinin stem flexibility and virus fusion kinetics.
    Winarski KL; Tang J; Klenow L; Lee J; Coyle EM; Manischewitz J; Turner HL; Takeda K; Ward AB; Golding H; Khurana S
    Proc Natl Acad Sci U S A; 2019 Jul; 116(30):15194-15199. PubMed ID: 31296560
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ching-fang-pai-tu-san inhibits the release of influenza virus.
    Hsieh CF; Yen HR; Liu CH; Lin S; Horng JT
    J Ethnopharmacol; 2012 Dec; 144(3):533-44. PubMed ID: 23041224
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The seafood Musculus senhousei shows anti-influenza A virus activity by targeting virion envelope lipids.
    Chen D; Lu S; Yang G; Pan X; Fan S; Xie X; Chen Q; Li F; Li Z; Wu S; He J
    Biochem Pharmacol; 2020 Jul; 177():113982. PubMed ID: 32305436
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Reduction of Influenza Virus Envelope's Fusogenicity by Viral Fusion Inhibitors.
    Rowse M; Qiu S; Tsao J; Yamauchi Y; Wang G; Luo M
    ACS Infect Dis; 2016 Jan; 2(1):47-53. PubMed ID: 27622947
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The inhibitory effect of sodium baicalin on oseltamivir-resistant influenza A virus via reduction of neuraminidase activity.
    Jin J; Chen Y; Wang D; Ma L; Guo M; Zhou C; Dou J
    Arch Pharm Res; 2018 Jun; 41(6):664-676. PubMed ID: 29572682
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dual-Action Heteromultivalent Glycopolymers Stringently Block and Arrest Influenza A Virus Infection
    Parshad B; Schlecht MN; Baumgardt M; Ludwig K; Nie C; Rimondi A; Hönzke K; Angioletti-Uberti S; Khatri V; Schneider P; Herrmann A; Haag R; Hocke AC; Wolff T; Bhatia S
    Nano Lett; 2023 Jun; 23(11):4844-4853. PubMed ID: 37220024
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
    Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
    Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
    [TBL] [Abstract][Full Text] [Related]  

  • 53. SARS-CoV-2 Evolutionary Adaptation toward Host Entry and Recognition of Receptor O-Acetyl Sialylation in Virus-Host Interaction.
    Kim CH
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32604730
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biological Evaluation of Uridine Derivatives of 2-Deoxy Sugars as Potential Antiviral Compounds against Influenza A Virus.
    Krol E; Wandzik I; Krejmer-Rabalska M; Szewczyk B
    Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28777309
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mycophenolic acid, an immunomodulator, has potent and broad-spectrum in vitro antiviral activity against pandemic, seasonal and avian influenza viruses affecting humans.
    To KKW; Mok KY; Chan ASF; Cheung NN; Wang P; Lui YM; Chan JFW; Chen H; Chan KH; Kao RYT; Yuen KY
    J Gen Virol; 2016 Aug; 97(8):1807-1817. PubMed ID: 27259985
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inhibition of influenza A virus infection by ginsenosides.
    Dong W; Farooqui A; Leon AJ; Kelvin DJ
    PLoS One; 2017; 12(2):e0171936. PubMed ID: 28187149
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Infection of Mouse Macrophages by Seasonal Influenza Viruses Can Be Restricted at the Level of Virus Entry and at a Late Stage in the Virus Life Cycle.
    Londrigan SL; Short KR; Ma J; Gillespie L; Rockman SP; Brooks AG; Reading PC
    J Virol; 2015 Dec; 89(24):12319-29. PubMed ID: 26423941
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeting the SARS-CoV-2 spike glycoprotein prefusion conformation: virtual screening and molecular dynamics simulations applied to the identification of potential fusion inhibitors.
    Romeo A; Iacovelli F; Falconi M
    Virus Res; 2020 Sep; 286():198068. PubMed ID: 32565126
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein Binding to ACE2 Receptors from Human, Pets, Farm Animals, and Putative Intermediate Hosts.
    Zhai X; Sun J; Yan Z; Zhang J; Zhao J; Zhao Z; Gao Q; He WT; Veit M; Su S
    J Virol; 2020 Jul; 94(15):. PubMed ID: 32404529
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir.
    Gubareva LV; Kaiser L; Matrosovich MN; Soo-Hoo Y; Hayden FG
    J Infect Dis; 2001 Feb; 183(4):523-31. PubMed ID: 11170976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.